Cell Source, Inc. (CLCS)

OTCMKTS: CLCS · Delayed Price · USD
-0.130 (-37.11%)
Feb 16, 2024, 3:17 PM EST - Market closed
Market Cap 8.48M
Revenue (ttm) n/a
Net Income (ttm) -5.61M
Shares Out 38.55M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,700
Open 0.460
Previous Close 0.350
Day's Range 0.220 - 0.460
52-Week Range n/a
Beta -151.38
Analysts n/a
Price Target n/a
Earnings Date n/a

About CLCS

Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 1
Stock Exchange OTCMKTS
Ticker Symbol CLCS
Full Company Profile

Financial Performance

Financial Statements


There is no news available yet.